SCHEMBL14564293

SCHEMBL14564293

COC(=O)[C@@H](C)Cc1ccc(C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ESR1 P03372 1/20 0.47
ESR2 Q92731 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ACACB O00763 1/20 0.46
P2RX3 P56373 1/20 0.46
HPGD P15428 1/20 0.45
ALDH1A1 P00352 1/20 0.44
THRB P10828 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PTPRB P23467 1/20 0.43
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
CXCR1 P25024 1/20 0.41
CXCR2 P25025 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14590363 1.00 ATM (0.50) ATML3MBTL1ESR1ESR2TDP1
SCHEMBL6575139 1.00 ATM (0.50) ATML3MBTL1ESR1ESR2TDP1
SCHEMBL15159080 0.86 ATM (0.46) ATML3MBTL1ESR1ESR2TDP1
SCHEMBL15933208 0.85 PPARG (0.48) ATML3MBTL1TDP1ACACBHPGD
SCHEMBL12142729 0.85 ALDH1A1 (0.48) ATMESR1ESR2HPGDALDH1A1
SCHEMBL15314148 0.85 ESR1 (0.65) ESR1ESR2SMN1; SMN2NPC1RAB9A
SCHEMBL4185343 0.85 ESR1 (0.65) ESR1ESR2SMN1; SMN2NPC1RAB9A
SCHEMBL13534766 0.85 ESR1 (0.47) L3MBTL1ESR1ESR2TDP1ACACB
SCHEMBL5546946 0.85 ESR1 (0.65) ESR1ESR2SMN1; SMN2NPC1RAB9A
SCHEMBL26937878 0.84 CA2 (0.47) ESR1ESR2TDP1ALDH1A1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130244929-A1 BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS MERCK SHARP & DOHME CORP. 2013-09-19 US disclosed
US-20110301349-A1 METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS TERSERA THERAPEUTICS LLC 2011-12-08 US disclosed
EP-1237878-B1 4-PYRIMIDINYL-N-ACYL-L-PHENYLALANINES HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130244929-A1 BRIDGED LIPOGLYCOPEPTIDES THAT POTENTIATE THE ACTIVITY OF BETA-LACTAM ANTIBACTERIALS SPPL2B, ENGASE, PEPD ATM 4169/4885L3MBTL1 1406/4885ESR1 2625/4885
US-20110301349-A1 METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS DPYD, TYMP, NUDT1 ATM 3018/4885L3MBTL1 4558/4885ESR1 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.